#1 Clinical Trials Search in Europe

PUCOTENLIMAB

PUCOTENLIMAB is an emerging immunotherapy drug being investigated in numerous clinical trials across multiple cancer types. As a PD-1 inhibitor, it works by helping the immune system recognize and attack cancer cells more effectively. Current trials are exploring PUCOTENLIMAB’s potential both as a standalone treatment and in combination with other therapies such as chemotherapy, targeted drugs, and radiation. These trials primarily focus on using PUCOTENLIMAB as neoadjuvant therapy (treatment before surgery) for various cancers including head and neck squamous cell carcinoma, rectal cancer, hepatocellular carcinoma, and cholangiocarcinoma, among others. This article summarizes the current research landscape of PUCOTENLIMAB in clinical trials and its potential impact on cancer treatment.

Table of Contents

What is Pucotenlimab?

Pucotenlimab is a humanized PD-1-specific monoclonal antibody that belongs to a class of drugs known as immune checkpoint inhibitors. It was approved by the National Medical Products Administration of China on September 29, 2022, for the treatment of patients with microsatellite highly unstable (MSI-H) or mismatch repair function defective (dMMR) solid tumors who have failed prior first-line and above systemic therapy[1].

This medication is being extensively studied across numerous clinical trials for its potential in treating various types of cancer, both as a standalone therapy and in combination with other treatments. The drug works by helping your immune system recognize and attack cancer cells more effectively.

How Does Pucotenlimab Work?

Pucotenlimab targets a protein called PD-1 (Programmed Death-1), which is found on the surface of your immune cells, particularly T cells. Under normal circumstances, PD-1 acts as a type of “off switch” that helps prevent T cells from attacking other cells in the body. Some cancer cells take advantage of this mechanism by expressing PD-L1, which binds to PD-1 and effectively “turns off” the T cells, preventing them from attacking the cancer[1].

By blocking the interaction between PD-1 and PD-L1, pucotenlimab “removes the brakes” on the immune system, allowing T cells to recognize and attack cancer cells. This approach is known as immunotherapy because it enhances your body’s natural defense mechanisms rather than directly targeting cancer cells like traditional chemotherapy.

Medical Conditions Treated with Pucotenlimab

Based on the clinical trials, pucotenlimab is being investigated for treating several types of cancer, including:

  • Head and Neck Squamous Cell Carcinoma (HNSCC) – Cancer that forms in the tissues of the head and neck regions[2]
  • Rhabdomyosarcoma – A type of cancer that develops in soft tissue, particularly skeletal muscle tissue[3]
  • Rectal Cancer – Cancer that begins in the rectum, the last several inches of the large intestine[4]
  • Intrahepatic Cholangiocarcinoma – A rare type of liver cancer that forms in the bile ducts within the liver[1]
  • Renal Cell Carcinoma – The most common type of kidney cancer in adults[5]
  • Endometrial Cancer – Cancer that begins in the lining of the uterus (endometrium)[6]
  • Lymphoepithelioma-like Carcinoma – A rare type of cancer characterized by the presence of numerous immune cells within the tumor[7]
  • Nasopharyngeal Carcinoma – Cancer that occurs in the nasopharynx, which is located behind your nose and above the back of your throat[8]
  • Cancer of Unknown Primary – A condition where cancer cells are found in the body, but the place where the cancer began is unknown[9]

Administration and Dosage

Based on the information from clinical trials, pucotenlimab is typically administered in the following ways:

  • Most commonly, pucotenlimab is given as an intravenous (IV) infusion, meaning it’s delivered directly into your bloodstream through a vein.
  • The standard adult dose is often 200 mg administered once every three weeks (Q3W)[10].
  • For pediatric patients, the dosage is sometimes calculated based on body weight, with doses ranging from 1 mg/kg to 6 mg/kg, not exceeding 200 mg[3].
  • Treatment cycles are typically repeated every 21 days (3 weeks).
  • The total number of treatment cycles varies depending on the specific cancer type, treatment protocol, and patient response, ranging from 3 to 8 cycles or more.

The exact dosage and schedule will be determined by your healthcare provider based on your specific condition, overall health, and other factors.

Combination Therapies

Pucotenlimab is often used in combination with other cancer treatments to enhance efficacy. Some common combination approaches include:

  • Pucotenlimab + Chemotherapy: Used in various cancers including head and neck cancers, rhabdomyosarcoma, and endometrial cancer. Common chemotherapy drugs used in combination include cisplatin, docetaxel, gemcitabine, paclitaxel, and carboplatin[2][3][6].
  • Pucotenlimab + Targeted Therapy: Combined with drugs like lenvatinib (a multi-kinase inhibitor) for treating cancers such as renal cell carcinoma and intrahepatic cholangiocarcinoma[1][5].
  • Pucotenlimab + Radiotherapy: Used in rectal cancer and other solid tumors where radiation can help shrink the tumor before surgery[4].
  • Pucotenlimab + Antibody-Drug Conjugates (ADCs): Combined with drugs like MRG003 (an EGFR-ADC) for cancers like head and neck squamous cell carcinoma[11].
  • Pucotenlimab + Bevacizumab + Other Agents: Used in complex regimens for certain cancers, such as rectal adenocarcinoma[12].

These combination approaches aim to attack cancer through multiple mechanisms simultaneously, potentially improving outcomes compared to single-agent treatments.

Neoadjuvant Therapy with Pucotenlimab

One of the most common applications of pucotenlimab in current clinical trials is as a neoadjuvant therapy. Neoadjuvant therapy refers to treatment given before the main treatment, which is often surgery. The goal is to shrink the tumor before surgical removal, making the operation easier or more effective[2][4].

Several clinical trials are investigating pucotenlimab as neoadjuvant therapy for various cancers:

  • Head and Neck Cancers: Pucotenlimab combined with chemotherapy (like TP regimen – cisplatin and docetaxel) before surgery[2].
  • Rectal Cancer: Pucotenlimab with radiotherapy and chemotherapy before deciding whether surgery is needed[4].
  • Liver Cancer: Pucotenlimab with lenvatinib and radiation therapy for resectable hepatocellular carcinoma with macrovascular invasion[13].
  • Endometrial Cancer: Pucotenlimab with carboplatin and paclitaxel before surgery[6].
  • Intrahepatic Cholangiocarcinoma: Pucotenlimab with other treatments to convert initially unresectable cancer to resectable disease[1].

The benefits of neoadjuvant therapy with pucotenlimab may include:

  • Shrinking the tumor to allow for less extensive surgery
  • Testing the tumor’s response to treatment
  • Potentially eliminating micrometastases (tiny cancer spread not visible on scans)
  • In some cases, achieving a complete response that might allow for organ preservation (avoiding surgery entirely)

Current Clinical Trials

Pucotenlimab is currently being evaluated in numerous clinical trials across different cancer types. These trials typically fall into different phases:

  • Phase I/II trials: These earlier-stage trials focus on determining the safety, proper dosage, and preliminary effectiveness of pucotenlimab. For example, a Phase I/II study is evaluating pucotenlimab combined with standard chemotherapy for intermediate/high-risk rhabdomyosarcoma in children and adolescents[3].
  • Phase II trials: These trials further assess effectiveness and monitor side effects. Multiple Phase II trials are investigating pucotenlimab in various settings, such as in combination with lenvatinib for non-clear cell renal cell carcinoma[5] or with neoadjuvant chemotherapy for advanced endometrial cancer[6].
  • Phase III trials: These larger trials compare the new treatment to standard treatments. For instance, a Phase III study is comparing MRG003 in combination with pucotenlimab versus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma[8].

Each trial has specific eligibility criteria, treatment protocols, and endpoints to measure success. If you’re interested in participating in a clinical trial involving pucotenlimab, discuss this with your healthcare provider who can help determine if you might be eligible for any ongoing studies.

Benefits and Outcomes

Clinical trials are evaluating various outcomes to measure the effectiveness of pucotenlimab treatment. Key outcomes being measured include:

  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. For example, in one study of pucotenlimab in patients with dMMR/MSI-H tumors, the ORR was 49.0%[1].
  • Pathological Complete Response (pCR): The absence of any cancer cells in tissue samples taken after treatment, which is a strong indicator of treatment success[4].
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not worsen[8].
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive[8].
  • Disease Control Rate (DCR): The percentage of patients whose disease is controlled (complete response, partial response, or stable disease)[1].
  • Conversion to Resectability: In some studies, success is measured by whether initially unresectable tumors become suitable for surgical removal after treatment[1].

These outcomes help researchers and healthcare providers determine the effectiveness of pucotenlimab for different cancer types and in different treatment approaches.

Safety and Side Effects

Like all medications, pucotenlimab may cause side effects. Based on clinical trial information, potential side effects may include:

  • Immune-related adverse events (irAEs): Since pucotenlimab works by activating the immune system, it can sometimes cause the immune system to attack healthy tissues. These effects can occur in various organs including the skin, liver, lungs, and endocrine glands[4].
  • Fatigue: Feeling extremely tired is a common side effect of many cancer treatments, including immunotherapy.
  • Gastrointestinal symptoms: These may include diarrhea, nausea, or abdominal pain.
  • Skin reactions: Rash, itching, or other skin changes may occur.
  • Fever: Some patients may experience elevated temperature during treatment.

In clinical trials, the severity of treatment-related adverse events is carefully monitored and graded according to established criteria like the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). For example, in one study, Grade ≥3 (severe) treatment-related adverse events were observed in 18 out of 100 patients receiving pucotenlimab[1].

It’s important to report any new symptoms or side effects to your healthcare provider promptly, as many side effects can be managed effectively if caught early.

Patient Considerations

If you’re considering treatment with pucotenlimab, either as part of a clinical trial or as an approved therapy, here are some important considerations:

  • Biomarker Testing: Some studies focus on specific biomarkers, such as MSI-H/dMMR status, EGFR positivity, or HER2 status. Your doctor may recommend testing to determine if pucotenlimab is likely to be effective for your specific cancer[9].
  • Treatment Schedule: Understand the time commitment involved, including frequency of infusions (typically every 3 weeks) and the total planned duration of therapy.
  • Monitoring: Regular check-ups and tests will be needed to monitor your response to treatment and watch for side effects.
  • Combination with Other Treatments: Be aware of potential interactions or additive side effects if pucotenlimab is being used alongside other cancer treatments.
  • Quality of Life: Some studies specifically assess how treatment affects your overall well-being using questionnaires like the FACT-Hep or FACT-C[1][12].
  • Follow-up Care: Even after completing treatment, regular follow-up will be important to monitor for any cancer recurrence or delayed side effects.

Always discuss these considerations with your healthcare team, who can provide personalized advice based on your specific situation, medical history, and treatment goals.

Cancer Type Trial Phase Combination Therapies Primary Outcome Measures Current Status
Rhabdomyosarcoma (pediatric) Phase I/II Standard chemotherapy regimen Dose-limiting toxicity; pathological complete response rate Recruiting
Head and Neck Squamous Cell Carcinoma (HNSCC) Phase II/III TP chemotherapy (Cisplatin and Docetaxel); MRG003 (EGFR-ADC) Pathological complete response rate; Objective response rate Recruiting
Rectal Cancer Phase II Radiotherapy and chemotherapy; CAPOX; Bevacizumab Clinical complete response rate; Pathological complete response rate Recruiting
Intrahepatic Cholangiocarcinoma Phase II HAIC (Hepatic artery infusion chemotherapy); Lenvatinib; DEB-TACE Number of patients amendable to curative surgical interventions Recruiting
Renal Cell Carcinoma (non-clear cell) Phase II Lenvatinib Objective Response Rate Recruiting
Endometrial Cancer Phase II Carboplatin and Paclitaxel Pathologic complete response Recruiting
Cancer of Unknown Primary (HER2-positive) Phase II MRG002 (HER2-ADC) Overall response rate Recruiting
Hepatocellular Carcinoma Phase II SBRT (Stereotactic Body Radiotherapy); Lenvatinib Objective response rate; Treatment complete rate Recruiting
Lymphoepithelioma-like Carcinoma (pediatric) Phase II Gemcitabine and Cisplatin Progression-free survival Recruiting
Nasopharyngeal Carcinoma (recurrent/metastatic) Phase III MRG003 vs. Chemotherapy (Gemcitabine, Docetaxel, or Capecitabine) Progression-Free Survival; Overall Survival Recruiting

FAQ

  • What type of drug is PUCOTENLIMAB? PUCOTENLIMAB is a humanized PD-1-specific monoclonal antibody, which belongs to a class of drugs called immune checkpoint inhibitors. It works by blocking the PD-1 pathway, which cancer cells often use to evade the immune system. By inhibiting this pathway, PUCOTENLIMAB helps the body's immune cells recognize and attack cancer cells more effectively.
  • What types of cancer is PUCOTENLIMAB being tested for? PUCOTENLIMAB is currently being tested in clinical trials for a wide range of cancers, including head and neck squamous cell carcinoma (HNSCC), rectal cancer, hepatocellular carcinoma (liver cancer), cholangiocarcinoma (bile duct cancer), rhabdomyosarcoma in children, endometrial cancer, renal cell carcinoma (kidney cancer), and lymphoepithelioma-like carcinoma in children and adolescents.
  • How is PUCOTENLIMAB administered to patients? PUCOTENLIMAB is typically administered as an intravenous (IV) infusion. In most trials, it is given at a dose of 200mg once every three weeks (Q3W), though some pediatric trials use weight-based dosing (such as 1 mg/kg, 3 mg/kg, or 6 mg/kg). The administration schedule may vary depending on the specific trial protocol and combination with other treatments.
  • What other treatments is PUCOTENLIMAB being combined with in clinical trials? PUCOTENLIMAB is being studied in combination with various other treatments, including standard chemotherapy regimens (like cisplatin, docetaxel, gemcitabine, paclitaxel), targeted therapies (like lenvatinib and MRG003, an EGFR-ADC), radiation therapy (including SBRT and brachytherapy), and other biological agents (like bevacizumab). These combinations aim to enhance treatment efficacy by attacking cancer through multiple mechanisms.
  • What is 'neoadjuvant therapy' and why is PUCOTENLIMAB being studied in this context? Neoadjuvant therapy refers to treatment given before the main treatment (usually surgery). PUCOTENLIMAB is being extensively studied as neoadjuvant therapy for various cancers to shrink tumors before surgery, potentially making them easier to remove. This approach may increase the chances of complete tumor removal, reduce the extent of surgery needed, and in some cases, allow for organ preservation. It may also help eliminate microscopic cancer cells that could cause recurrence later.

Ongoing Clinical Trials on PUCOTENLIMAB

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • PD-1 (Programmed Death-1): A protein on the surface of immune cells (T cells) that normally helps keep these cells from attacking other cells in the body. When PD-1 binds to PD-L1 on cancer cells, it stops T cells from killing the cancer cells. PD-1 inhibitors like PUCOTENLIMAB block this binding and boost the immune response against cancer cells.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. PUCOTENLIMAB is a monoclonal antibody designed to target and bind to PD-1.
  • Neoadjuvant Therapy: Treatment given before the primary treatment, usually surgery. For cancer, this often involves chemotherapy, radiation therapy, or both to shrink a tumor before attempting to remove it surgically.
  • Clinical Trial: A research study that tests how well new medical approaches work in people. These studies test new methods of screening, prevention, diagnosis, or treatment of a disease.
  • Phase I/II Trial: Phase I trials test a new drug's safety, dosage range, and side effects. Phase II trials continue to test safety and begin to evaluate how well the drug works. Combined Phase I/II trials do both simultaneously.
  • Phase III Trial: Large-scale trials that compare the new treatment to standard treatments to see which works better. These often involve hundreds or thousands of patients across multiple sites.
  • Response Rate: The percentage of patients whose cancer shrinks or disappears after treatment. Complete response (CR) means all detectable cancer has disappeared, while partial response (PR) means the cancer has shrunk but not completely disappeared.
  • Pathological Complete Response (pCR): The absence of all cancer cells in a tissue sample after treatment, determined by examining the tissue under a microscope. In cancer treatment, achieving pCR often indicates a better prognosis.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either diagnosis or the start of treatment that patients are still alive.
  • RECIST: Response Evaluation Criteria In Solid Tumors – a set of rules used to assess how well a cancer patient responds to treatment. It defines when tumors shrink, stay the same, or grow.
  • mRECIST: Modified RECIST – an adaptation of RECIST that takes into account the viable (living) tumor tissue, often used in liver cancer evaluations.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • EGFR-ADC: Epidermal Growth Factor Receptor-Antibody Drug Conjugate – a targeted therapy that combines an antibody targeting EGFR (a protein often overexpressed in cancer cells) with a cancer-killing drug.
  • SBRT: Stereotactic Body Radiation Therapy – a highly precise radiation treatment that delivers very high doses of radiation to small, well-defined tumors while minimizing damage to surrounding healthy tissue.
  • Rhabdomyosarcoma: A type of cancer that develops in soft tissue (specifically skeletal muscle tissue) and can occur anywhere in the body. It's one of the most common soft tissue sarcomas in children.
  • HNSCC: Head and Neck Squamous Cell Carcinoma – cancers that begin in squamous cells that line the moist surfaces inside the head and neck, such as the mouth, nose, and throat.
  • MSI-H/dMMR: Microsatellite Instability-High/Deficient Mismatch Repair – genetic characteristics of some tumors where cells have a high number of mutations due to impaired DNA repair mechanisms. These tumors often respond well to immunotherapy.
  • Q3W: Every 3 weeks – a dosing schedule where medication is administered once every three weeks.

References

  1. https://clinicaltrials.gov/study/NCT06192797
  2. https://clinicaltrials.gov/study/NCT06895369
  3. https://clinicaltrials.gov/study/NCT06456892
  4. https://clinicaltrials.gov/study/NCT06770270
  5. https://clinicaltrials.gov/study/NCT06129955
  6. https://clinicaltrials.gov/study/NCT06561308
  7. https://clinicaltrials.gov/study/NCT06969534
  8. https://clinicaltrials.gov/study/NCT06976190
  9. https://clinicaltrials.gov/study/NCT06869174
  10. https://clinicaltrials.gov/study/NCT06959108
  11. https://clinicaltrials.gov/study/NCT06530914
  12. https://clinicaltrials.gov/study/NCT06872606
  13. https://clinicaltrials.gov/study/NCT06524466